FDA OKs Another Drug for Early Alzheimer’s Disease

The FDA approved donanemab (Kisunla) for the treatment of adults with early symptomatic Alzheimer’s disease with confirmed amyloid pathology, the agency announcedopens in a new tab or window Tuesday. This includes Alzheimer’s patients with mild cognitive impairment and mild dementia.

The once-monthly treatment is the only anti-amyloid agent with evidence to support stopping therapy when amyloid plaques

https://www.medpagetoday.com/neurology/alzheimersdisease/110934